Connection

Richard Friedman to Arthroplasty, Replacement, Hip

Back to Details
This is a "connection" page, showing publications Richard Friedman has written about Arthroplasty, Replacement, Hip.
Richard Friedman
Connection Strength
5.866
Arthroplasty, Replacement, Hip
  1. Effects of the Obesity Epidemic on Total Hip and Knee Arthroplasty Demographics. J Arthroplasty. 2021 09; 36(9):3097-3100.
    View in: PubMed
    Score: 0.682
  2. Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):771-8.
    View in: PubMed
    Score: 0.446
  3. Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty. J Bone Joint Surg Am. 2014 Feb 19; 96(4):272-8.
    View in: PubMed
    Score: 0.415
  4. Complication rates after hip or knee arthroplasty in morbidly obese patients. Clin Orthop Relat Res. 2013 Oct; 471(10):3358-66.
    View in: PubMed
    Score: 0.393
  5. Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost. 2012 Jul; 108(1):183-90.
    View in: PubMed
    Score: 0.366
  6. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban. Expert Rev Pharmacoecon Outcomes Res. 2011 Jun; 11(3):299-306.
    View in: PubMed
    Score: 0.343
  7. Limit the bleeding, limit the pain in total hip and knee arthroplasty. Orthopedics. 2010 Sep; 33(9 Suppl):11-3.
    View in: PubMed
    Score: 0.326
  8. Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty--insights from the Multinational Global Orthopaedic Registry (GLORY). Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):14-21.
    View in: PubMed
    Score: 0.326
  9. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010 Sep; 126(3):175-82.
    View in: PubMed
    Score: 0.319
  10. New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty. Orthopedics. 2009 Dec; 32(12 Suppl):79-84.
    View in: PubMed
    Score: 0.310
  11. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost. 2009 Sep-Oct; 15 Suppl 1:25S-31S.
    View in: PubMed
    Score: 0.302
  12. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin. 2008 Jan; 24(1):87-97.
    View in: PubMed
    Score: 0.271
  13. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg. 2007 Mar; 15(3):148-55.
    View in: PubMed
    Score: 0.256
  14. Extended thromboprophylaxis after hip or knee replacement. Orthopedics. 2003 Feb; 26(2 Suppl):s225-30.
    View in: PubMed
    Score: 0.193
  15. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop Relat Res. 2000 Jan; (370):171-82.
    View in: PubMed
    Score: 0.156
  16. Making Tranexamic Acid the Standard of Care in Hip and Knee Arthroplasty: Commentary on an article by Brian Hallstrom, MD, et al.: "The Michigan Experience with Safety and Effectiveness of Tranexamic Acid Use in Hip and Knee Arthroplasty". J Bone Joint Surg Am. 2016 10 05; 98(19):e86.
    View in: PubMed
    Score: 0.124
  17. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vasc Health Risk Manag. 2014; 10:157-67.
    View in: PubMed
    Score: 0.104
  18. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res. 2012 Nov; 130(5):818-20.
    View in: PubMed
    Score: 0.093
  19. Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons. J Arthroplasty. 2012 May; 27(5):659-66.e5.
    View in: PubMed
    Score: 0.088
  20. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011 Apr; 105(4):721-9.
    View in: PubMed
    Score: 0.084
  21. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26; 358(26):2765-75.
    View in: PubMed
    Score: 0.070
  22. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res. 2008 Aug; 466(8):2009-11; author reply 2012-4.
    View in: PubMed
    Score: 0.070
  23. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br. 2007 Jun; 89(6):799-807.
    View in: PubMed
    Score: 0.065
  24. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 Mar; 83(3):336-45.
    View in: PubMed
    Score: 0.042
  25. Lessons learned from the global orthopaedic registry: study design, current practice patterns, and future directions. Am J Orthop (Belle Mead NJ). 2010 Sep; 39(9 Suppl):29-31.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.